Q3 2026 Financial Results
Zeige 283 Suchergebnisse
Grifols presents new AMBAR® data from a real-world observational study in patients with Alzheimer’s disease
Grifols increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26
Half of Spaniards are unaware that plasma can be donated separately from blood
Grifols strengthens evidence supporting the AMBAR® program in Alzheimer’s disease with real-world evidence data
Grifols signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain
Grifols announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency
Veröffentlichungen
Links zu unseren neuesten Finanz- und Nachhaltigkeitsberichten und anderen aktuellen Veröffentlichungen.
Medienkontakte
Wenn Sie als Journalist oder Medienvertreter eine Frage haben, wenden Sie sich bitte an unser Media Relations Team.